Publications by authors named "Kenneth Algazy"

Claim this Profile
A
A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN).
Surbhi Grover, Nandita Mitra, Fei Wan, John N Lukens, Sonam Sharma, Kenneth Algazy

Am J Clin Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M Algazy, Tracey L Evans

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Jessica Bauman, Corey Langer, Harry Quon, Kenneth Algazy, Alexander Lin

Exp Ther Med· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.
Matthew G Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy

J Natl Compr Canc Netw· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous smoking cessation before lung cancer diagnosis.
Barbara G Campling, Bradley N Collins, Kenneth M Algazy, Robert A Schnoll, Miu Lam

J Thorac Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.
David I Rosenthal, Clifton David Fuller, Mitchell Machtay, Kenneth M Algazy, Dan M Meyer

J Thorac Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
Maria Luisa Veronese, Kenneth Algazy, Lisa Bearn, Beth Eaby, Jane Alavi

Cancer Invest· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based study of lung carcinoma in Pennsylvania: comparison of Veterans Administration and civilian populations.
Barbara G Campling, Wei-Ting Hwang, Jiameng Zhang, Stephanie Thompson, Leslie A Litzky, Kenneth M Algazy

Cancer· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
Keith T Flaherty, James P Stevenson, Maryann Redlinger, Kenneth M Algazy, Bruce Giatonio

Cancer Chemother Pharmacol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
Joshua H Bilenker, James P Stevenson, Keith T Flaherty, Kenneth Algazy, Kathy McLaughlin

Cancer Chemother Pharmacol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Mitchell Machtay, Jason H Lee, James P Stevenson, Joseph B Shrager, Kenneth M Algazy

J Thorac Cardiovasc Surg· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.
Keith T Flaherty, James P Stevenson, Maryann Gallagher, Bruce Giantonio, Kenneth M Algazy

Cancer· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.
Weijing Sun, James P Stevenson, James M Gallo, Maryann Redlinger, Daniel Haller, Kenneth Algazy

Clin Cancer Res· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and molecular features of small cell lung cancer.
Allyson M Campbell, Barbara G Campling, Kenneth M Algazy, Wafik S el-Deiry

Cancer Biol Ther· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
James P Stevenson, Weijing Sun, Maryann Gallagher, Robert Johnson, David Vaughn, Kenneth Algazy

Clin Cancer Res· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer.
David I Rosenthal, Sue S Yom, Li Liu, Mitchell Machtay, Kenneth Algazy

Invest New Drugs· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spinner's hematuria.
Kenneth M Algazy

N Engl J Med· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis